Integer Holdings Co. (NYSE:ITGR - Get Free Report) has earned an average recommendation of "Buy" from the nine brokerages that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $145.00.
A number of research firms have recently commented on ITGR. Truist Financial set a $150.00 price objective on shares of Integer and gave the stock a "buy" rating in a report on Friday, April 25th. Benchmark reduced their price objective on shares of Integer from $150.00 to $140.00 and set a "buy" rating for the company in a report on Friday, April 25th. Raymond James raised their price objective on shares of Integer from $145.00 to $150.00 and gave the stock an "outperform" rating in a report on Friday, April 25th. Citigroup raised shares of Integer from a "hold" rating to a "strong-buy" rating and raised their price objective for the stock from $133.00 to $140.00 in a report on Thursday, May 22nd. Finally, Wall Street Zen raised shares of Integer from a "sell" rating to a "hold" rating in a report on Monday, May 19th.
View Our Latest Analysis on Integer
Integer Stock Performance
Shares of NYSE ITGR traded down $0.23 during trading hours on Monday, hitting $119.16. 99,114 shares of the stock were exchanged, compared to its average volume of 512,475. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.95 and a quick ratio of 2.09. The company's 50 day moving average is $118.55 and its 200 day moving average is $128.89. The firm has a market capitalization of $4.16 billion, a P/E ratio of 35.46, a P/E/G ratio of 1.72 and a beta of 1.03. Integer has a one year low of $104.93 and a one year high of $146.36.
Integer (NYSE:ITGR - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The medical equipment provider reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.27 by $0.04. Integer had a net margin of 6.92% and a return on equity of 11.65%. The business had revenue of $437.39 million during the quarter, compared to the consensus estimate of $428.51 million. During the same period in the prior year, the firm earned $1.14 EPS. Integer's quarterly revenue was up 7.3% compared to the same quarter last year. On average, research analysts expect that Integer will post 6.01 EPS for the current year.
Insider Buying and Selling at Integer
In other news, CEO Joseph W. Dziedzic sold 338,975 shares of the stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $123.17, for a total transaction of $41,751,550.75. Following the completion of the sale, the chief executive officer now owns 47,000 shares of the company's stock, valued at $5,788,990. This represents a 87.82% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 2.16% of the company's stock.
Institutional Investors Weigh In On Integer
Large investors have recently made changes to their positions in the stock. Mather Group LLC. grew its position in Integer by 304.3% in the fourth quarter. Mather Group LLC. now owns 190 shares of the medical equipment provider's stock valued at $25,000 after purchasing an additional 143 shares in the last quarter. Lee Danner & Bass Inc. acquired a new stake in shares of Integer during the 4th quarter worth about $27,000. AdvisorNet Financial Inc acquired a new stake in shares of Integer during the 1st quarter worth about $28,000. Opal Wealth Advisors LLC acquired a new stake in shares of Integer during the 1st quarter worth about $28,000. Finally, Bessemer Group Inc. lifted its stake in shares of Integer by 73.1% during the 1st quarter. Bessemer Group Inc. now owns 296 shares of the medical equipment provider's stock worth $35,000 after buying an additional 125 shares during the last quarter. Institutional investors own 99.29% of the company's stock.
Integer Company Profile
(
Get Free ReportInteger Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.
Recommended Stories

Before you consider Integer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Integer wasn't on the list.
While Integer currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.